Navigation Links
Combination therapy improves survival time for patients with advanced liver cancer
Date:11/16/2010

Treatment of inoperable advanced liver cancer with the agent doxorubicin (routinely used to treat this condition) in addition to the agent sorafenib resulted in greater overall survival and progression-free survival, compared to patients who received treatment with doxorubicin alone, according to a study in the November 17 issue of JAMA.

"Hepatocellular [liver] carcinoma (HCC) is the sixth most common malignancy worldwide, with approximately 600,000 new cases per year. Patients with inoperable or metastatic disease have a median [midpoint] survival of only a few months. Despite the lack of a clear survival benefit, doxorubicin has become a routinely and widely used agent in the treatment of HCC," according to background information in the article. Sorafenib has shown a statistically significant increase in median overall survival compared to placebo. A phase 1 study assessing the feasibility and tolerability of sorafenib in combination with doxorubicin for patients with solid tumors has shown promise. The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial.

Ghassan K. Abou-Alfa, M.D., of Memorial Sloan-Kettering Cancer Center, New York, and colleagues conducted a randomized, phase 2 study of doxorubicin plus sorafenib and doxorubicin plus placebo in patients with advanced HCC. The study, conducted from April 2005 to October 2006, included 96 patients (76 percent male; median age, 65 years) who were randomly assigned to receive doxorubicin intravenously every 21 days plus either sorafenib or placebo orally twice a day. The date of the last patient's follow-up was April 2008.

Following complete accrual, an unplanned early analysis for efficacy was performed by the independent data monitoring committee, so the trial was halted. The 2 patients remaining in the placebo group at that time were offered sorafenib.

There were 51 total time-to-disease progression
'/>"/>

Contact: Kathleen Harrison
HarrisoK@mskcc.org
646-227-3956
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2

Related medicine news :

1. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
2. Combination therapy more effective for enlarged prostate
3. Combination Treatment May Help Depressed Alcoholics
4. Researchers find new chemotherapy combination shows promise in endometrial cancer
5. Leeza Gibbons and ZERONA Equals a Winning Combination
6. Combination antibiotics effective against chlamydia-induced arthritis
7. Hair Loss Doctor Overcomes Odds To Produce First Ever Combination Topical Hair Growth Formula
8. Combination therapy targets stubborn leukemia stem cells
9. Combination treatment regimen not effective against advanced melanoma
10. New combination effective against pancreatic cancer
11. Noninvasive combination technique may reduce number of breast biopsies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 DiaperBuys, a national online ... Aging’ Month this September. Healthy Aging Month was started ... the nation on the positive aspects of growing older. ... conditions or side effects from medications that cause urinary ... Manager for DiaperBuys.com. “This can seem daunting to some ...
(Date:9/16/2014)... 16, 2014 Banish headaches forever with ... approved Cefaly device for chronic migraine relief and treatment. ... the United States. Until now, US patients would directly ... in Belgium and wait 2-3 weeks for their device ... United States and once prescription and payment is received, ...
(Date:9/16/2014)... Reading, MA (PRWEB) September 16, 2014 ... announce its partnership with Fairfax Egg Bank. The collaboration ... and expand the donor egg offering at the Fertility ... operated since 2006 and offers the nation’s largest selection ... is advantageous for several reasons:, , ...
(Date:9/15/2014)... (PRWEB) September 16, 2014 The team ... Carey Danis & Lowe report that the ... was found responsible for the injuries that a woman ... to treat stress urinary incontinence (SUI). , Carey Danis ... medical device litigation and personal injury law. The St. ...
(Date:9/15/2014)... 2014 Hastings and Hastings, an experienced ... announces one flat attorney fee for personal injury cases. ... the largest portion possible of their settlement or recovery ... and damaged personal property. In addition, Hastings and Hastings ... simply states that no fees are due unless a ...
Breaking Medicine News(10 mins):Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 2Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 3Health News:Cefaly Migraine Treatment Device Now Readily Available For Widespread Purchase in United States 2Health News:FCNE Announces Partnership with Fairfax Egg Bank 2Health News:Carey Danis & Lowe Reports On $73 Million Boston Scientific Verdict 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 3
... , SAN BERNARDINO, Calif., Aug. 11 ... its customers and employees recently raised $266,429.00 to benefit the Leukemia ... has raised over $460,000 for this organization. , , ... the month of June 2009, Stater Bros., customers and employees at ...
... , WASHINGTON, Aug. 11 Even while ... is showing hospitals owned and operated by physicians among the best in the ... of "healthcare reform." , , The independent testing and research ... patients around the country. Overwhelmingly, Cons u mer ...
... Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) ... the U.S. Food and Drug Administration,s (FDA) complete response ... trazodone. , As previously announced, Labopharm received a complete ... indicating the Company,s new drug application (NDA) for its ...
... public survey conducted in Europe found that the vast ... and prostate cancer screening, according to a new study ... the National Cancer Institute . Gerd Gigerenzer, of ... and colleagues conducted a survey of over 10,200 people ...
... , , , , ... SCOR ), a leader in measuring the digital world, today ... the effects of increasing U.S. unemployment on online consumer activity. While ... substantial declines, there has been a corresponding increase in the number ...
... Healthcare reform has become a hot button issue for politicians and ... clear the air and separate fact from fiction. , , ... e QtY97yVQFUg6so , , ... and unrestricted use at http://www.medi a ...
Cached Medicine News:Health News:Stater Bros. Raises $266,429.00 for the Leukemia & Lymphoma Society 2Health News:Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block 2Health News:Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block 3Health News:Labopharm submits response to FDA for novel antidepressant 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 3
(Date:9/15/2014)... 2014 /PRNewswire-iReach/ -- CaPtivate Pharmaceuticals LLC, a ... phosphate (CaP)-based nanoparticle drug and vaccine delivery technologies, ... License Agreement with Immunotope Inc., another ... for the treatment and prevention of viral infections ... of the agreement, Immunotope is granted a non-exclusive ...
(Date:9/15/2014)... , Sept. 15, 2014 PDL BioPharma, Inc. (PDL) ... has paid the September 12, 2014, regular quarterly dividend payment ... of PDL as of September 5, 2014, the record date. ... BioPharma manages a portfolio of patents and royalty assets, ... patents and license agreements with various biotechnology and pharmaceutical ...
(Date:9/15/2014)... DUBLIN , Sept. 15, 2014 ... "Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014" ... (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 presents comprehensive ... Europe , Asia , ... The report includes paracetamol (acetaminophen) description, covers its ...
Breaking Medicine Technology:CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 2CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 3PDL BioPharma Completes Regular Quarterly Dividend Payment 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 3
... 2012 Mylan Inc. (Nasdaq: MYL ) today announced its ... Financial Results Adjusted diluted EPS of ... for the same prior year period, an increase of 18%; ... 31, 2011 compared to $1.61 for the prior year, an increase of ...
... CITY, N.J., Feb. 21, 2012 S1 Pharmaceuticals, Inc. ... New Drug (IND) application to the U.S. Food and ... (Lorexys).  Lorexys is the Company,s lead drug candidate for ... Female Sexual Dysfunction (FSD).  Lorexys, clinical ...
Cached Medicine Technology:Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 2Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 3Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 4Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 5Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 6Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 7Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 8Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 9Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 10Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 11Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 12Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 13Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 14Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 15Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 16S1 Pharmaceuticals Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) 2
... The R4Mplus offers global companies ... help meet RFID compliance initiatives. With ... a variety of connectivity options, and ... is a super value. Plus, the ...
... The 105SL combines enhanced memory, ... rugged and reliable all-metal construction. ... processing and print speed make ... users who value reliability, productivity, ...
... R4Mplus offers global companies a cost-effective ... RFID compliance initiatives. With die-cast metal ... of connectivity options, and complex multi-language ... super value. Plus, the fully integrated ...
... Ideal for patient wristband printing, the ... reliable and accurate scanning for improved patient ... text, and graphics on a variety of ... printer prints patient ID wristbands on demand. ...
Medicine Products: